Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective

Hagar I Labouta^{1

2

3

4}, Robert Langer^#^{5

6}, Pieter R Cullis^#⁷, Olivia M Merkel^#⁸, Mark R Prausnitz^#⁹, Yasmine Gomaa⁹, Sara S Nogueira^{10

11}, Tushar Kumeria^{12

13}

Affiliations

¹ College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, R3E 0T5, Canada. hagar.labouta@umanitoba.ca.
² Biomedical Engineering, University of Manitoba, Winnipeg, MB, Canada. hagar.labouta@umanitoba.ca.
³ Children's Hospital Research Institute of Manitoba, Winnipeg, MB, R3E 3P4, Canada. hagar.labouta@umanitoba.ca.
⁴ Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt. hagar.labouta@umanitoba.ca.
⁵ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
⁶ Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
⁷ Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.
⁸ Department of Pharmacy, Pharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-University, 81337, Munich, Germany.
⁹ School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
¹⁰ School of Materials Science and Engineering, University of New South Wales, Kensington, Sydney, NSW, 2052, Australia.
¹¹ Australian Centre for NanoMedicine, University of New South Wales, Kensington, Sydney, NSW, 2052, Australia.
¹² School of Materials Science and Engineering, University of New South Wales, Kensington, Sydney, NSW, 2052, Australia. t.kumeria@unsw.edu.au.
¹³ Australian Centre for NanoMedicine, University of New South Wales, Kensington, Sydney, NSW, 2052, Australia. t.kumeria@unsw.edu.au.

^# Contributed equally.

PMID: 35290656
PMCID: PMC8923087
DOI: 10.1007/s13346-022-01146-1

Review

Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective

Hagar I Labouta et al. Drug Deliv Transl Res. 2022 Nov.

. 2022 Nov;12(11):2581-2588.

doi: 10.1007/s13346-022-01146-1. Epub 2022 Mar 15.

Authors

Hagar I Labouta^{1

2

3

4}, Robert Langer^#^{5

6}, Pieter R Cullis^#⁷, Olivia M Merkel^#⁸, Mark R Prausnitz^#⁹, Yasmine Gomaa⁹, Sara S Nogueira^{10

11}, Tushar Kumeria^{12

13}

Affiliations

¹ College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, R3E 0T5, Canada. hagar.labouta@umanitoba.ca.
² Biomedical Engineering, University of Manitoba, Winnipeg, MB, Canada. hagar.labouta@umanitoba.ca.
³ Children's Hospital Research Institute of Manitoba, Winnipeg, MB, R3E 3P4, Canada. hagar.labouta@umanitoba.ca.
⁴ Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt. hagar.labouta@umanitoba.ca.
⁵ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
⁶ Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
⁷ Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.
⁸ Department of Pharmacy, Pharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-University, 81337, Munich, Germany.
⁹ School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
¹⁰ School of Materials Science and Engineering, University of New South Wales, Kensington, Sydney, NSW, 2052, Australia.
¹¹ Australian Centre for NanoMedicine, University of New South Wales, Kensington, Sydney, NSW, 2052, Australia.
¹² School of Materials Science and Engineering, University of New South Wales, Kensington, Sydney, NSW, 2052, Australia. t.kumeria@unsw.edu.au.
¹³ Australian Centre for NanoMedicine, University of New South Wales, Kensington, Sydney, NSW, 2052, Australia. t.kumeria@unsw.edu.au.

^# Contributed equally.

PMID: 35290656
PMCID: PMC8923087
DOI: 10.1007/s13346-022-01146-1

Abstract

The triumphant success of mRNA vaccines is a testimony to the important role drug delivery technologies have played in protecting billions of people against SARS-CoV-2 (or the Corona Virus Disease 2019; COVID-19). Several lipid nanoparticle (LNP) mRNA vaccines were developed and have been instrumental in preventing the disease by boosting the immune system against the pathogen, SARS-CoV-2. These vaccines have been built on decades of scientific research in drug delivery of mRNA, vaccines, and other biologicals. In this manuscript, several leading and emerging scientists in the field of drug delivery share their perspective on the role of drug delivery technologies in developing safe and efficacious vaccines, in a roundtable discussion. The authors also discussed their viewpoint on the current challenges, and the key research questions that should drive this important area of research.

Keywords: COVID-19 vaccine; Drug delivery; Lipid nanoparticles; Microneedles; Polymeric formulations.

PubMed Disclaimer

Conflict of interest statement

H.I.L, Y.G, S.S.N, and T.K confirm that they have no competing interests. M.R.P. is an inventor of microneedle patents, is a paid advisor, and is a founder/shareholder of companies developing microneedle-based products (Micron Biomedical). This potential conflict of interest has been disclosed and is managed by Georgia Tech. O.M.M is a consultant for AbbVie Deutschland GmbH, for PARI Pharma GmbH, and an advisory board member for Coriolis Pharma GmbH. PC is a co-founder of Acuitas Therapeutics, Precision NanoSystems, and NanoVation Therapeutics and has financial holdings in Acuitas and NanoVation. R.L. served on Alnylam’s founding scientific advisory board, is also a co-founder of Moderna, and holds equity in both companies. For a list of entities with which R.L. is, or has been recently involved, compensated, or uncompensated, see https://www.dropbox.com/s/yc3xqb5s8s94v7x/Rev%20Langer%20COI.pdf?dl=0

References

1. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–1094. doi: 10.1038/s41578-021-00358-0. - DOI - PMC - PubMed
1. Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16(6):630–643. doi: 10.1038/s41565-021-00898-0. - DOI - PubMed
1. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817–838. doi: 10.1038/s41573-021-00283-5. - DOI - PMC - PubMed
1. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976;263(5580):797–800. doi: 10.1038/263797a0. - DOI - PubMed
1. Thevenot J, Troutier A-L, David L, Delair T, Ladavière C. Steric stabilization of lipid/polymer particle assemblies by Poly(ethylene glycol)-lipids. Biomacromol. 2007;8(11):3651–3660. doi: 10.1021/bm700753q. - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective

Affiliations

Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous